RECRUITING

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Talk to us

Conditions

Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory PolyneuropathyImmune-Mediated NeuropathyNeuropathyIntravenous ImmunoglobulinIVIGTS-HDS antibodyFGFR-3 antibodyFGFR3 antibodyImmune mediated small fiber neuropathyPanzygaPlexin D1 antibody

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will enroll patients with small fiber neuropathy (SFN). The study will look at an intravenous immunoglobulin (IVIG) called Panzyga. Panzyga is approved by the FDA as a therapy for Primary humoral immunodeficiency (PI) in patients 2 years of age and older; Chronic immune thrombocytopenia (ITP) in adults and Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. It has not been approved by the FDA for use in SFN. There is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies in great numbers in SFN patients. The primary outcome is quantified improvement in intraepidermal nerve fiber density (IENFD) on repeat skin punch biopsy after 6 months of IVIG treatment.

Official Title

Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial

Quick Facts

Study Start:2023-12-15
Study Completion:2028-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04153422

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Patients ≥ age 18
  2. 2. Patient with clinical and biopsy evidence of pure small fiber neuropathy (with or without dysautonomia) as evidenced by reduced IENFD on skin biopsy using PGP 9.5 as the immunostain. Biopsy must have been performed within 12 months of study enrollment. If biopsies were not done at CRL, they will be repeated and done at 3 sites (upper and lower thigh, lower calf), to have consistent and equivalent biopsy data with the follow up biopsy done after 6 mos of treatment
  3. 3. Patients must have elevated and/or abnormal titers of autoantibodies to TS-HDS-IgM, FGFR3-IgG, or Plexin-D1 measured by the Washington University Neuromuscular Laboratory (St Louis) within 12 mos of enrollment
  4. 4. Patients must have a baseline pain score on a visual analogue scale (VAS) of Greater or equal to 4/10
  5. 5. Patients must have a baseline Utah Early Neuropathy Scale (UENS) score of Greater or equal to 4/10
  6. 6. Small Fiber Neuropathy Screening List (SFNSL) score of 11/84 or greater
  7. 7. Non-pregnant, non-lactating female. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during treatment
  1. 1. Any other known cause for small fiber neuropathy other than the presence of the elevated titers of TS-HDS-IgM, FGFR3-IgG, or Plexin-D1 autoantibodies
  2. 2. Patients with generalized, severe musculoskeletal conditions other than SFN that prevent a sufficient assessment of the patient by the physician
  3. 3. Electromyography/nerve conduction study (EMG/NCS) evidence of large fiber polyneuropathy, to be confirmed by study PI
  4. 4. Underlying severe heart, kidney, liver disease, or HIV infection, (Note: If there is no previous HIV test result documented within the last 5 years, a test may be performed in order to confirm eligibility)
  5. 5. Patients with a history of deep vein thrombosis within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or deep vein thrombosis
  6. 6. Known significant IgA deficiency with antibodies to IgA
  7. 7. History of hypersensitivity, anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of IVIG 10%
  8. 8. Known blood hyperviscosity, or other hypercoagulable states
  9. 9. Use of IgG products within six months prior to enrollment
  10. 10. Patients with a history of drug or alcohol abuse within the past five years prior to enrollment
  11. 11. Patients unable to understand or unwilling or unable to comply with the study protocol

Contacts and Locations

Study Contact

Anna Pham
CONTACT
8475034344
APham@northshore.org
May Aunaetitrakul
CONTACT
8475702570

Principal Investigator

Lawrence Zeidman, MD, FAAN
PRINCIPAL_INVESTIGATOR
Endeavor Health

Study Locations (Sites)

Endeavor Health
Evanston, Illinois, 60201
United States

Collaborators and Investigators

Sponsor: Endeavor Health

  • Lawrence Zeidman, MD, FAAN, PRINCIPAL_INVESTIGATOR, Endeavor Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-15
Study Completion Date2028-02-28

Study Record Updates

Study Start Date2023-12-15
Study Completion Date2028-02-28

Terms related to this study

Keywords Provided by Researchers

  • Small Fiber Neuropathy
  • Neuropathy
  • Intravenous Immunoglobulin
  • IVIG
  • TS-HDS antibody
  • FGFR-3 antibody
  • FGFR3 antibody
  • Immune mediated small fiber neuropathy
  • Panzyga
  • Plexin D1 antibody

Additional Relevant MeSH Terms

  • Small Fiber Neuropathy
  • Autoimmune Small Fiber Neuropathy
  • Inflammatory Polyneuropathy
  • Immune-Mediated Neuropathy